Login / Signup

CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.

Elisa AgostinettoVéronique DebienGuilherme Nader MartaMatteo LambertiniMartine Piccart-GebhartEvandro de Azambuja
Published in: European journal of clinical investigation (2021)
Treatment landscape for HER2+ breast cancer is rapidly changing, and CDK4/6 and PI3K inhibitors represent a new promising strategy to improve patients' outcomes.
Keyphrases